{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:15:47Z","timestamp":1793718947596,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["204710"],"award-info":[{"award-number":["204710"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaip.2023.07.024","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T19:04:54Z","timestamp":1690398294000},"page":"3650-3661.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Mark C.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Pilette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife C.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert W.","family":"Jakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.07.024_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaci.2015.11.020","article-title":"Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1","volume":"138","author":"Hinks","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.07.024_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaip.2017.06.008","article-title":"Comorbidities in difficult-to-control asthma","volume":"6","author":"Hekking","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.07.024_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12948-018-0103-x","article-title":"Comorbidities are associated with different features of severe asthma","volume":"16","author":"Novelli","year":"2018","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/resp.13026","article-title":"Co-morbidities in severe asthma: clinical impact and management","volume":"22","author":"Porsbjerg","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2023.07.024_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \"treatable traits\" in difficult asthma: current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.07.024_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04656-2020","article-title":"The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories","volume":"58","author":"Marcon","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib10","doi-asserted-by":"crossref","first-page":"s36","DOI":"10.7861\/clinmedicine.18-2-s36","article-title":"Diagnosis and treatment of severe asthma: a phenotype-based approach","volume":"18","author":"Jones","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jaip.2023.07.024_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1183\/09031936.00121308","article-title":"Influence of comorbid conditions on asthma","volume":"33","author":"Boulet","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib14","first-page":"P973","article-title":"Effect of oral corticosteroids on symptomatuc reflux in severe allergic asthma: is there a link?","volume":"44","author":"Aziz","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1378\/chest.121.2.625","article-title":"Oral corticosteroids increase esophageal acid contact times in patients with stable asthma","volume":"121","author":"Lazenby","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.07.024_bib17","doi-asserted-by":"crossref","first-page":"00039","DOI":"10.1183\/23120541.00039-2016","article-title":"A\u00a0multidisciplinary team case management approach reduces the burden of frequent asthma admissions","volume":"2","author":"Burke","year":"2016","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2023.07.024_bib18","doi-asserted-by":"crossref","first-page":"00215","DOI":"10.1183\/23120541.00215-2022","article-title":"Multidisciplinary care in chronic airway diseases: the Newcastle model","volume":"8","author":"McDonald","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2023.07.024_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.07.024_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.07.024_bib21","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V78.10.2542.2542","article-title":"Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils","volume":"78","author":"Yamaguchi","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.07.024_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","article-title":"Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine","volume":"9","author":"Pavord","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.07.024_bib26","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD Effectiveness and Safety of mepolizumab in a multicentric spanish cohort of asthma\u00a0patients\u00a0stratified by eosinophils: the REDES Study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2023.07.024_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"super-responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.07.024_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an\u00a0examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib30","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid\u2013sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.07.024_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12067","article-title":"Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports","volume":"11","author":"Pini","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/JAA.S275944","article-title":"Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma","volume":"13","author":"Silver","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taille","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JAA.S40244","article-title":"Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases","volume":"8","author":"Menzella","year":"2015","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid\u2013sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.07.024_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.05.021","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities","volume":"127","author":"Casale","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.07.024_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2023.07.024_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2023.07.024_bib43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","article-title":"Cluster analysis and characterization of response to mepolizumab. A step closer to personalized\u00a0medicine for patients with severe asthma","volume":"11","author":"Ortega","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2023.07.024_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused\u00a0review of the impact data in the literature","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/cea.13882","article-title":"Real-world omalizumab and mepolizumab treated difficult asthma phenotypes and their clinical outcomes","volume":"51","author":"Fong","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in\u00a0severe\u00a0eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2023.07.024_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1378\/chest.126.1.59","article-title":"Asthma as a risk factor for COPD in a longitudinal study","volume":"126","author":"Silva","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.07.024_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thorax.58.4.322","article-title":"Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up","volume":"58","author":"Vonk","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2023.07.024_bib49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.07.024_bib50","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1164\/rccm.202110-2265OC","article-title":"Mucus plugs persist in asthma, and changes in mucus plugs associate with\u00a0changes in airflow over time","volume":"205","author":"Tang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib51","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/COPD.S105988","article-title":"Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation","volume":"11","author":"Kitaguchi","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jaip.2023.07.024_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib54","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41533-022-00306-7","article-title":"Addressing sex and gender to improve asthma management","volume":"32","author":"Boulet","year":"2022","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib56","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1442-2050.2012.01399.x","article-title":"Association of gastroesophageal reflux disease with asthma control","volume":"26","author":"Liang","year":"2013","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.jaip.2023.07.024_bib57","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01634-2021","article-title":"Vulnerability to acid reflux of the airway epithelium in severe asthma","volume":"60","author":"Perotin","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.07.024_bib58","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/all.14297","article-title":"Human airway epithelial cells express a functional IL-5 receptor","volume":"75","author":"Barretto","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.rmed.2013.12.012","article-title":"Anxiety, depression and personality traits in severe, prednisone-dependent asthma","volume":"108","author":"Amelink","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.735030","article-title":"The management of extrapulmonary comorbidities and treatable traits; obesity, physical inactivity, anxiety, and depression, in adults with asthma","volume":"2","author":"McLoughlin","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2023.07.024_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/ers.12.34","article-title":"Asthma and mental health among youth: etiology, current knowledge and future directions","volume":"6","author":"Goodwin","year":"2012","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/rmed.2000.0968","article-title":"Psychological disorder in asthma is associated with\u00a0poor control and poor adherence to inhaled steroids","volume":"95","author":"Cluley","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.07.024_bib63","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823007973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823007973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:20:38Z","timestamp":1716441638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823007973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2213219823007973"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.07.024","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}